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I. Introduction
Pre-eclampsia/eclampsia is a serious condition that can develop during pregnancy, even in women 
with no risk factors. Although there is little understanding of what causes pre-eclampsia/eclampsia, 
there is an effective treatment for this condition which, if left untreated, can progress to coma and 
death. In 1994, the World Health Organization (WHO) recommended magnesium sulfate as the 
standard treatment for pre-eclampsia and eclampsia and within two years it was placed on WHO’s 
Essential Medicines List. Despite its known efficacy, this inexpensive drug is often underutilized, in 
part because the diffusion of innovation takes time but also because of the service delivery challenges 
inherent to the use of magnesium sulfate—it requires a strong and effective referral system, often a 
challenge in under-resourced health systems. The underutilization of magnesium sulfate has been a 
recognized problem in Nigeria for some time; prior to 2007 there was almost no magnesium sulfate 
in the country.1
The significant contribution of pre-eclampsia/eclampsia to maternal mortality in Nigeria—along with 
the promise of magnesium sulfate as a solution—caught the attention of the John D. and Catherine 
T. MacArthur Foundation in 2005 when a program officer overheard a conversation between two 
Nigerian doctors who were lamenting the failure of a piece of equipment in their hospital labora-
tory that was used for manufacturing magnesium sulfate. Without it, one was saying to the other, 
they would have no supply of the drug to treat pre-eclampsia/eclampsia and no way to save women’s 
lives. The Foundation decided to fund a series of grants to expand the use of magnesium sulfate for 
pre-eclampsia/eclampsia in Nigeria and, in 2014, commissioned an evaluation of that work. This case 
study describes the findings of the evaluation, including the challenges encountered while implement-
ing the projects, the successes achieved, and existing opportunities for future scaling up of the ser-
vices across the country.
II. The Evaluation Process
In 2014, the MacArthur Foundation commissioned the Public Health Institute to conduct a process 
evaluation of the grants the Foundation had made to expand the use of magnesium sulfate as a treat-
ment for pre-eclampsia/eclampsia in Nigeria. The purpose of the evaluation was to gain a deeper 
understanding of how these programs were implemented, where they were successful, and where they 
still face obstacles to scale up. A team of experts conducted a desk review of literature and grantee 
reports, interviewed global experts and local key informants and stakeholders (see Appendix A), and 
visited the program sites. Most of the data was gathered using qualitative methodologies: interviews 
with key stakeholders and evaluator observations during site-visits. In addition, available quantitative 
data was reviewed, with a focus on training records and hospital and health center service statistics 
gathered by grantees. The evaluation was carried out between June and November 2014.
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III. Background
Magnesium Sulfate for Pre-eclampsia and Eclampsia—A Simple But 
Challenging Treatment
Pre-eclampsia is a pregnancy complication that results when a woman develops high blood pressure 
and an excess of protein in the urine after the 20th week of pregnancy (it is most common after the 
32nd week). Left untreated, pre-eclampsia progresses to eclampsia, a condition of severe convulsions 
and sometimes coma. There is no way to predict who will develop the condition during pregnancy, but 
some women are at higher risk: women who are having their first pregnancy; women younger than 
20 and older than 35 years; and women pregnant with multiples (e.g., twins). Identification of high-risk 
women is key to early treatment and overall reduction of maternal mortality and morbidity, particu-
larly in low-resource settings.2,3 Treatment of pre-eclampsia with magnesium sulfate has been shown to 
significantly lower the risk of eclampsia (by 58%) and the risk of mortality (by 45%).4-6 The treatment 
has a very low incidence of severe side effects and mortality attributable to the drug is extremely rare 
(0.01%).2,7 With treatment, the symptoms of the condition are temporarily relieved though the health 
risk remains (the only cure for eclampsia is to deliver the pregnancy). In fact, the initial treatment is 
often so effective at quickly relieving symptoms that many women (and even some providers) mistak-
enly think that the problem has been solved. 
From the patient’s perspective, there is little warning before the onset of symptoms. This is especially 
true for women who have limited access to antenatal care and therefore do not have their blood pres-
sure monitored. By the time a woman starts experiencing noticeable symptoms, such as vomiting, gas-
tric pain, and headaches, the condition has progressed to a point where she requires immediate medical 
attention. If the woman knows to seek treatment and if she can get to a facility where treatment is 
available, the condition can often be managed for long enough to provide emergency delivery care. If 
she does not get care, she and the fetus will most likely die.
From the provider’s perspective, treating pre-eclampsia or eclampsia using magnesium sulfate requires 
training and attention to detail. The drug must be mixed into solution using a specific dosing algorithm 
just prior to use (once prepared it remains stable only for 24 hours), and overdosing can be a concern. 
The first “loading” dose is large, often resulting in discomfort to the woman. Subsequent doses also 
need be carefully measured and timed, adding to the clinical complexity of treatment. And, decision 
making regarding the progression of treatment through delivery requires good clinical judgment to 
properly assess the severity of the condition against the maturity of the fetus. 
From a health systems perspective, providing magnesium sulfate involves, at minimum, ensuring its 
ready availability in the drug supply system (along with needed injection and intravenous supplies), staff-
ing hospitals with trained providers, sensitizing women and their families to the signs of pre-eclampsia 
and eclampsia and need to seek care, and ensuring an adequate referral system from the primary 
healthcare level to hospital-based care. Ideally, services would also include the ability to provide the 
loading dose at the primary healthcare level with referral for continued treatment.
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In summary, while the solution to treating eclampsia seems simple—get magnesium sulfate into the 
woman’s blood stream and deliver the fetus as soon as possible—doing so in time and correctly is com-
plicated and involves many steps and many players.8
The MacArthur Foundation’s Funding Initiative—Grant-making for Alliance 
and Action
The initial conversation that sparked the MacArthur Foundation’s interest in solving the problems of 
magnesium sulfate use in Nigeria brought to light the challenge that two doctors faced in accessing a 
supply of the product for use in their hospital after their compounding equipment broke down. While 
fixing the broken piece of equipment would have been an immediate solution to that problem, the 
Foundation recognized the need for a more sustainable and comprehensive solution to the problem of 
drug supply. As a first step, the Foundation made a grant to Oxford University which convened a meet-
ing of major stakeholders, including a leading pharmaceutical firm in Nigeria, to generate interest in the 
provision of magnesium sulfate; that firm went on to become the major supplier of the drug to Nigeria 
and other governments. The Foundation also recognized that drug supply alone would not guarantee 
successful access; coordinated and sustained efforts would be needed to support the entire comple-
ment of healthcare services necessary to provide the drug to the women who needed it. As a result of 
this broader perspective, the Foundation supported myriad activities including: constituency building; 
public advocacy; research and evaluation; and community outreach and capacity building, in addition to 
efforts to address product supply (see Figure 1).
Research and
Evaluation
Constituency
Building
Policy
Advocacy
Reduce Maternal 
Mortality due to 
Pre-Eclampsia/Eclampsia
Product 
Supply
Community 
Outreach
Capacity 
Building
Figure 1. Interrelated strategies for expanding use of magnesium sulfate in Nigeria
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In addition, fully aware of the difficulties in taking a good idea to scale in a country already challenged 
by an overtaxed health infrastructure (see box, The Challenge of Scale Up, below), the Foundation 
designed its approach with the following key elements of successful scale up in mind: 
 n Creating a vision and broad strategy;
 n Legitimizing the approach;
 n Building a constituency;
 n Realigning and mobilizing resources;
 n Modifying organizational structures;
 n Coordinating action;
 n Monitoring performance.9 
The Challenge of Scale Up
A significant challenge for any health system is to bring successful pilot projects to national 
scale and sustain innovations. While it is often assumed that scale up will easily follow a 
successful pilot, the realities surrounding pilot project implementation (significant funding, 
strengthened infrastructure in the pilot project site) are very different from the realities 
faced by health systems managers as they try to expand the model (limited funding, com-
peting health priorities, weak infrastructure). The average time for taking a successful pilot 
to national scale is 15 years.9
Research suggests that, to have the best chance of being widely adopted, innovations must 
be:
 n A relevant solution to an important, perceived problem; 
 n An improvement over existing practices;
 n Supported by evidence and, ideally, endorsed by credible sources;
 n Observable so that potential users can see the results in practice;
 n Easy to transfer and adopt;
 n Compatible with the system’s established values, norms, and facilities; and
 n Able to be tested for feasibility before committing the potential user to full scale up.
All of these conditions clearly apply to magnesium sulfate as an intervention to address 
the problem of pre-eclampsia/eclampsia in Nigeria, thereby providing a strong foundation 
for successful scale up.
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IV. Projects Funded and Activities Implemented
Beginning in 2007, the MacArthur Foundation made a series of grants to both public (Federal Ministry 
of Health) and private organizations (Population Council, Society of Gynecology and Obstetrics of 
Nigeria, EngenderHealth, and Ipas) to integrate the use of magnesium sulfate into the Nigerian health 
system. The grantees (with the exception of Ipas which started its work later) worked synergistically 
and carried out concurrent activities that addressed product supply, tested and evaluated new proto-
cols, expanded the model, and built capacity.
Addressing supply issues
It was generally believed that the biggest issue in Nigeria around magnesium sulfate was the persistent 
unavailability of the drug. Stakeholders cited two reasons for this problem: the lack of profitability of 
making the drug and the inability of the government medical stores logistics systems to keep it in good 
supply. In addition to the supply issues, historically there had been little demand for the drug due to the 
complexity of dosing, including the provider fear of toxicity with overdose.
In 2007, the MacArthur Foundation brought together stakeholders from the Federal Ministry of Health 
and UNICEF to focus on the supply of magnesium sulfate in the country. The initial plan was to use 
the well-established and secure UNICEF supply chain to address supply and distribution issues, with 
recognition that ultimately state governments needed to put in place good and sustained procurement, 
supply, and tracking policies to avoid stockouts and pilferages. The Population Council purchased the 
drug for the initial pilot activities (with funds from the MacArthur Foundation) and the Federal Ministry 
of Health followed this with a large purchase (900,000 doses) to ensure that all 36 states and the 
Federal Capital Territory (Abuja) were included in the national scale up plan (also with support from 
the Foundation). 
Research and evaluation
In 2008, the MacArthur Foundation funded the Population Council to carry out an introductory pilot 
project in Kano State in northern Nigeria; doctors and midwives from ten state health facilities were 
trained to use a simplified protocol (modified Pritchard regimen) to administer magnesium sulfate. In 
addition, the project conducted community sensitization efforts focused on helping women and their 
families identify the signs and symptoms of pre-eclampsia and worked with community health extension 
workers and traditional birth attendants to address the need for recognition of the danger signs, treat-
ment, and referral. The project demonstrated a significant drop in the case fatality rate due to eclamp-
sia—from 20.9% before the start of services to 2.3% after—and there was no significant difference in 
the cost of using magnesium sulfate over the standard treatment of diazepam.10 The significant drop in 
mortality and the cost effectiveness of the magnesium sulfate intervention encouraged the Kano State 
government to scale up the intervention to the remaining 26 hospitals in the state.10 The Population 
Council produced a national curriculum for the use of magnesium sulfate to treat pre-eclampsia and 
eclampsia as part of this early work.
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Expansion of the model
As a result of the compelling evidence from Kano, the MacArthur Foundation provided additional 
support to the Society of Obstetrics and Gynecology of Nigeria (SOGON) to expand the magnesium 
sulfate work to six states (Kano, Plateau, Enugu, Borno, Cross River, and Lagos) with the introduc-
tion of the drug in one hospital in each state. The focus of the SOGON work was to draw atten-
tion to magnesium sulfate as a proven medical intervention and to strengthen policies and provider 
capabilities to make treatment with magnesium sulfate more widely available. SOGON engaged at 
the state government level to raise awareness and advocate for state policies, using its members to 
visit health officials throughout each of the designated states. Beyond its work with clinicians and the 
health system, SOGON provided public health education on issues relating to obstetrical emergency 
care in the project states. Once again, the significant case fatality drop (from 15.1% to 2.7%) across 
the six state hospitals lent local legitimacy to the use of the drug to treat pre-eclampsia and eclamp-
sia.11 The snowball effect from these results allowed for the scale up and expansion of magnesium 
sulfate into other states.
Capacity building
A grant made to the Federal Ministry of Health in 2008 enabled the Federal Ministry of Health to focus 
on institutionalizing delivery of magnesium sulfate throughout the healthcare system, building on the 
trainings that were already occurring as part of that institution’s Integrated Maternal, Newborn, and 
Child Health initiative. The Ministry allied itself with the Nigerian Medical Association and the National 
Association of Nigerian Nurses and Midwives, as well as with Obstetrics and Gynecology department 
heads and chief pharmacists of selected tertiary health institutions in each state to integrate magnesium 
sulfate into existing clinical services. They also conducted trainings, both in-service and pre-service, in 
170 institutions across all 36 state and the Federal 
Capital Territory; through a process of step-down 
trainings, approximately 1,818 doctors were trained. 
Figure 2 shows the incremental process to scale up 
of services. 
As the expansion progressed, it became clear 
that efforts to initiate treatment at the primary 
care level were also needed; by the time women 
reached the hospital, the condition had often 
progressed past the point of effective treatment. 
A continuing grant to the Population Council in 
2011 enabled focused attention at the primary 
healthcare and community levels to assess how 
best to involve traditional birth attendants, com-
munity health extension workers, and nurses in 
identification, immediate clinical care, and refer-
ral. The Population Council conducted opera-
tions research in 20 primary care facilities—10 
with a task- shifting intervention and 10 without 
Figure 2. The expansion of magnesium sulfate for treat-
ment of pre-eclampsia and eclampsia in Nigeria  
Year 2008 2009 2010*
States 1 11 36
Hospitals 10 (then 36) 48 400+
Staff trained 185 100’s 1000’s
*Note: Although all states have received some level of train-
ing, the progress to scale up of services ranges from only 
training in some states to integration into multiple hospitals 
in others. 
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the intervention. By documenting the need for and advocating for policy and protocol changes, the 
Population Council gained approval for task-shifting to community health extension workers so that 
the initial loading dose could be provided at the primary healthcare level. The work also involved eth-
nographic research to determine the factors influencing the observed delay in women seeking treat-
ment and to develop ways to facilitate more successful referral for further care.
The MacArthur Foundation has continued to find ways to integrate magnesium sulfate into ongoing 
work and build capacity. For example, Ipas received support in 2013 to train medical interns about 
comprehensive maternal care; the training integrates information about the key causes of maternal 
mortality and trains medical interns to correctly use various effective interventions, including magne-
sium sulfate for pre-eclampsia and eclampsia.
V. Evaluation Findings: Successes and Remaining Challenges
In the whole of Kano state, prior to this project there was only one doctor at 
Murtala Muhammad Specialist Hospital who occasionally used magnesium sulfate 
to treat eclampsia when he was on shift and the drug was in stock. Consequently 
there was high mortality from eclampsia, with a case fatality rate of around 18.5% 
and accounting for close to 40% of maternal mortality in the state. However this 
significantly changed with the coming of the project. The case fatality rate from 
eclampsia is now around 2–3% and mortality from other maternal causes has now 
overtaken eclampsia. And all these resulted from a simple training of one and a 
half days. —Consultant at Amino Kano Teaching Hospital
By successfully implementing the Foundation’s multi-faceted strategy and paying attention to the necessary 
steps in the scale up process, grantees have collectively made significant progress towards the full integra-
tion of the use of magnesium sulfate into the Nigerian healthcare system. Figure 3 provides an overview of 
how the specific approaches used by grantees aligned with the recommended steps for scale up.9
Figure 3. Alignment of project approaches with steps in the scale up process
Legitimize Change
• WHO-approved approach
• Credible local champions
• Evidence from pilot
Coordinate Action
• Complementary organizational 
    partnerships
• Clear roles for service 
   delivery, training, advocacy
Build a Constituency
• Stakeholder engagement 
• Provider advocacy (SOGON)
• Community outreach
Modify Organizational Structures
• Strengthened drug supply system
• Built service delivery capacity
• Institutionalized training 
   (in service and pre-service)
Track Performance and 
Maintain Momentum
• Monitoring to track results
• Adapted approaches
• Dissemination through study tours
Realign and Mobilize Resources
• Transition funding from 
   MacArthur
• Integrated into existing services
   to reduce cost burden
Primary Linkage
Secondary Linkage
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Notable achievements in the process to scale up the use of magnesium sulfate in Nigeria, as captured 
from discussions with key stakeholders and informants, include:
 n The use of the drug was legitimized and integrated through the effective use of research and 
evaluation; 
 n Stakeholders were engaged, support from and action by other organizations was galvanized, and 
a national constituency was built;
 n Tasks were shifted to include community health extension workers; 
 n Financial resources were realigned and mobilized;
 n National guidelines and curricula were created and implemented, and the referral system and 
patient compliance with referrals were bolstered; and
 n Drug supply channels were strengthened and systems put in place to monitor the distribution 
system. 
Research successfully generated evidence
Documenting and proving the utility and success of magnesium sulfate was instrumental to legitimiz-
ing its use and ensuring the continued engagement of health ministries and institutions. The rigorous 
research led by the Population Council helped to seat the work within wider international evidence on 
the topic and helped stakeholders: 1) realize and understand the dynamics of the complexities of admin-
istering the correct doses of magnesium sulfate; and 2) recognize that midwives, nurses, and community 
health extension workers could safely administer the loading dose of the drug and then provide accu-
rate referral information and action.
Remaining challenges—More operations research is needed to continue to scale up the program and 
overcome obstacles to full implementation. For example, it was reported that the quality of the clinical 
services needs to be improved. The correct use of magnesium sulfate is very inconsistent and there is 
the need to address the underlying factors that prevent health workers from providing magnesium sul-
fate according to acceptable standards, including:
 n Resistance to change from what the providers are used to, complicated by the fact that the pro-
tocol for the administration of magnesium sulfate is much more cumbersome than that of diaz-
epam (the previously used but less effective drug for pre-eclampsia and eclampsia);
 n Inadequate number of trained staff as a result of transfers, retirements, and attrition; and
 n Failure to follow the protocol to refer and/or deliver the woman of her pregnancy (sometimes 
even sending her home), mainly due to the misperception that the loading dose of magnesium 
sulfate—which effectively stops convulsions—has treated the problem.
Stakeholders were engaged and a constituency was built
Diligent engagement with the government at every step of the program ensured the sustained atten-
tion of state officials, as well as medical and nursing successes with the drug, which helped to achieve 
the necessary support, including at top levels of the government. The role played by the Society 
of Gynecology and Obstetrics of Nigeria (SOGON) was judged by key informants as particularly 
EXPANDING USE OF MAGNESIUM SULFATE FOR TREATMENT OF PRE-ECLAMPSIA AND ECLAMPSIA   11
important in legitimizing the intervention and gaining acceptance of the project by government officials 
at the national level; SOGON members and other health professionals engaged by them became the 
loudest advocates of magnesium sulfate to the government.
Medical and health practitioners, initially the biggest obstacle to the introduction 
of these technologies and interventions, turned out to be its biggest advocates 
once they were convinced. This turned out to be the most important outcome of 
advocacy and it led the government’s speedy acceptance of the interventions. 
 —Key informant
At the state level, the project cultivated champions within the Obstetrics and Gynecology community 
to spur local action needed to introduce and sustain a robust level of effort with magnesium sulfate. 
For instance, oft-mentioned by respondents was the leadership of the then Director General of Kano 
State Health Services Management Board, who helped galvanize the state government’s interest in 
 magnesium sulfate.
The Director of the State Health Services cancels every other appointment 
to attend and make sure he addresses any issue related to magnesium sulfate 
brought to him. Certainly without his leadership and support the introduction of 
magnesium sulfate would not have been so successful. 
 —Key informant
Remaining challenge—Continuing the advocacy and engagement with policymakers as well as with 
new medical and nursing staff is critical to build on the achievements and maintain the momentum that 
has been gained. The full integration of magnesium sulfate into the curricula and standards of care in 
Nigeria is new and still very vulnerable as is documented by the following:
Within just few months of its introduction, mortality from eclampsia fell to zero 
in all intervention facilities. However after December 2005, mortality from 
eclampsia returned to its pre-pilot period in all the facilities. It was then we 
realized how important advocacy is to the introduction of a drug or service, no 
matter how good it is. If we had done good advocacy, the government would 
have taken over and we may not have had a return to the pre-magnesium sulfate 
period in terms of mortality from eclampsia in those facilities. 
 —Key informant
Tasks were shifted to include community health extension workers
One element of successful scale up is the modification of existing organizational structures to achieve 
the desired outcome. A key outcome of the program was the operations research that demonstrated 
successful task shifting to include the community health extension workers in the administration of the 
treatment protocol. The Population Council’s research at the hospital and community level revealed 
that the women in need of the life-saving drug resided mostly in rural areas, prompting a pilot study 
and program to train community health extension workers to administer the first loading dose and 
then refer the patient. The results of that study led to a change in national health policies to now allow 
community health extension workers to administer the drug and refer cases for continued care. This 
proved critical to addressing better the needs of rural women:
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The task-shifting aspects of the effort have been most important, especially in 
the North of Nigeria where it is especially difficult for women to access health 
services. —Key informant
Remaining challenges—The evaluation identified two significant problems with the referral system: 
 n Referral from primary healthcare facilities to magnesium sulfate intervention sites was not timely, 
resulting in women dying at the referral site (it was noted that most fatal cases of eclampsia were 
those referred from the primary healthcare level). Since most primary healthcare facilities have 
not benefited from the intervention and scale up efforts, major problems remain in terms of tim-
ing and effectiveness of referral from these locations; and
 n Many patients who received a loading dose failed to complete the referral process to a higher 
level facility for delivery; in one study, 90% of women who received the loading dose did not 
complete the referral process.12 Because of a sense of immediate relief and the belief that the 
worst was over, some patients did not comply with referral instructions to get further care. And 
even those that did get to the referral level facilities often failed to understand that the loading 
dose only stabilized them and they were still at risk; providers reported that the rapid resolu-
tion of symptoms provided by the loading dose often resulted in patients asking to be discharged 
home. These failures to adhere to the referral process, by both the women and providers, 
account for some of the deaths seen in the program.12
There is an ongoing need for community-based education on the symptoms of pre-eclampsia/eclampsia 
as well as need for medical care even beyond the initial relief of the loading dose of magnesium sulfate. 
The rates of institutional births and births attended by a skilled birth attendant are still low throughout 
Nigeria and especially in the north. From the perspectives of the healthcare workers interviewed, the 
lack of community sensitization and awareness significantly affected their interventions with magnesium 
sulfate. The role of community education and sensitization was acutely noted as important to remedy 
delays in care.
National guidelines, curricula, and job aides were created
One hallmark success of the magnesium sulfate introduction work was the development of national 
service delivery guidelines and training curricula for the use of magnesium sulfate to treat pre-
eclampsia and eclampsia and their subsequent integration into the national healthcare system. The 
development of a clear protocol (including guidelines and algorithms for the administration of mag-
nesium sulfate) for training of all levels of service providers, including community health extension 
workers, was a collaborative effort between the Federal Ministry of Health, EngenderHealth, the 
Population Council, SOGON, State Health Commissioners, and other partner organizations. With 
the assistance of state-level actors and community stakeholders, these efforts permeated down to 
Local Government Areas, including at the health facility and community levels. Job aides helped to 
solidify correct practice: 
Knowledge has been imparted. The algorithms provided to each provider were 
helpful in guiding treatment and in providing on the job training to new providers 
 —Key informant
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Remaining challenge—Continued monitoring is important to make sure that the new guidelines and 
curricula are included in the training of all new healthcare workers. As proved to be the case with 
stakeholder engagement, the achievements of the initiative could easily be lost if attention is not paid 
to enforcing the new guidelines. It will be important to continue this advocacy for many years, until the 
curricula is viewed as integral to medical and nursing training.  
Partners have begun to address drug supply issues
Working closely with the Federal Ministry of Health and partners, the project has begun to address 
problems with the supply of magnesium sulfate. In the beginning, grantees reported frequent stockouts 
of magnesium sulfate and other needed supplies such as urinalysis strips and sphygmomanometers. To 
address this supply problem the Population Council increased the focus on effective monitoring, requi-
sitioning, and distribution of drugs at program facilities. 
Key informants noted that the enhanced monitoring of magnesium sulfate supplies had a positive effect 
on reducing stockouts not only of magnesium sulfate but of other medicines as well.13 And in Kano 
state, the increased focus on effective monitoring, requisitioning, and distribution of drugs at engaged 
facilities and at the administrative level was believed to have positively affected other aspects of the 
health system. 
It [the project] built confidence in the health system. There was obvious boost in 
the morale of health workers and consequent increase in the confidence they have 
in the health system… there was obvious decrease in mortality and morbidity and 
health workers themselves saw firsthand the wonders of magnesium sulfate with 
evidence and therefore became some of its most important advocates.  
 —Maternal and Child Health Coordinator in Kano State
Remaining challenges—Much still needs to be done to strengthen drug supply channels as there 
are frequent stockouts of magnesium sulfate throughout the country. Other supplies and equipment 
critical for the management of patients with pre-eclampsia and eclampsia, such as urinalysis strips and 
sphygmomanometers, are also often not available or dysfunctional. In Kano State, these commodities 
are supplied as part of the Kano State Free Medical Services Scheme. Most respondents did not freely 
admit to lack of magnesium sulfate in the facilities where they work. However, every service provider 
interviewed maintained that the reason magnesium sulfate supply was never exhausted at the general 
hospitals was because health workers in the hospitals would only provide the loading dose of the drug, 
requiring patients to purchase the additional doses needed for treatment from the private sector (mag-
nesium sulfate appears to be readily available through hospital pharmacies). (Note: according to one 
study conducted in 2013, 62.2% of the cases required families of the women to purchase the drug for 
use after the loading dose.)12
For any eclamptic woman brought to our facility, we provide only the loading dose 
free. If she requires maintenance she has to purchase from outside the hospital. If 
we provide 100% of doses required by every eclampsia patient, the supply will not 
be enough for us. 
 —Matron in labor room, Kano
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VI. Recommendations for Moving Forward
Nigeria is well on its way to fully integrating the use of magnesium sulfate in its maternal health ser-
vices. The impressive work that has been done needs to be sustained and numerous obstacles over-
come if true scale is to be achieved. Recommended actions to address remaining challenges include: 
 n Ensure continuum of care from home to hospital;
 n Adopt targeted social and behavior change strategies to increase hospital births;
 n Improve public sector supply and logistics system for magnesium sulfate; and
 n Focus on integration of services.
Ensure continuum of care from home to hospital 
Community-based advocacy and engagement of community leaders, counsellors, and health workers 
for education about the signs and symptoms of pre-eclampsia is very important if treatment using mag-
nesium sulfate is to be effective. In addition, an effective referral system is crucial because the first part 
of the treatment—the loading dose—only buys time and does not resolve the problem. Most providers 
interviewed noted that the eclampsia mortality seen in the hospitals largely comes from cases referred 
from Primary Health Centers, located in the communities. Practical ways to improve the effectiveness 
of home to hospital continuum of care include: 
 n Help households identify the danger signs of pregnancy and understand need for referral through 
trainings of community resource persons (such as traditional birth attendants) and by involving 
women’s advocacy groups in the community;
 n Capitalize on the recent policy changes on task-shifting to devolve the administration of the loading 
dose of magnesium sulfate to the community health extension workers at Primary Health Centers;
 n Help communities solve their referral transport challenges; 
 n Improve the quality of antenatal care services by ensuring that needed supplies are available and 
developing a checklist that will help improve the detection of pre-eclampsia at antenatal care 
 visits; and
 n Improve the quality of the care women receive in the health facilities so they will trust the 
 services and not avoid using them.
Adopt targeted social and behavior change strategies to increase hospital 
births
The high frequency of home-based births in Nigeria makes preventable causes of death like eclampsia 
very devastating and difficult to control. Because the full regimen of magnesium sulfate must be com-
pleted at the hospital level, channels must be explored to ensure that women at risk are detected early 
and moved to hospital. Eventually ways to encourage and ensure hospital delivery in all the regions of 
the country—rural or urban—must be pursued. A model that recognizes the pregnant woman as a 
consumer who will make choices based on personal, societal, and structural influences can help iden-
tify barriers and suggest possible interventions. Enlisting the support of women’s advocacy groups to 
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generate demand for quality maternal health services while improving the quality of the interpersonal 
care provided in facilities will help build trust in the delivery services. A mistrust of health services, 
and of hospitals in particular, poses an almost insurmountable barrier to reducing the risk of eclampsia. 
Generating a public demand for woman-friendly delivery services is an approach that could be condu-
cive in Nigeria, given the predominance and strength of women’s advocacy groups in the country.
Improve public sector supply and logistics system for magnesium sulfate
Ensuring a consistent and adequate supply of magnesium sulfate continues to be a significant challenge. 
The general state of the government’s free maternal health medical services program—which was 
designed to improve access to health services including essential health commodities—was frequently 
mentioned by respondents as a key reason why the government’s magnesium sulfate scale up has not 
been fully realized. This is because the supply of magnesium sulfate as part of the free medical ser-
vices is now being affected by the irregularity of the free medical supplies. To compound the situation, 
healthcare workers reported being afraid to inform patients that there are no commodities available for 
fear of being accused of sabotaging the government. 
While magnesium sulfate is readily available in the private sector, health workers in the public sector 
have created their own solution to the supply problem—all facilities visited reported providing only the 
loading dose because of inadequacy of supply. In order to ensure the sustainability of national scale up 
of magnesium sulfate, the public supply and distribution channels must be stocked and monitored. This 
can be achieved through strategic policy and advocacy work with the National Primary Health Care 
Development Agency and its state counterparts and is feasible given the expected increase in funding 
for Primary Health Care through the National Health Act, the proposed Village Health Worker pro-
gram, and the new focus by major donors (including the Gates Foundation) on strengthening primary 
healthcare services.
Focus on integration and coordination
The next phase of work to fully scale up the use of magnesium sulfate for the treatment of pre-eclamp-
sia and eclampsia in Nigeria, will need to focus on integrating the services within all the levels of the 
healthcare system: 
National level—Close integration with the efforts of the National Primary Health Care Development 
Agency (NPHCDA) and its maternal health programs (chiefly the Midwives Service Scheme and the 
Subsidy Reinvestment and Empowerment Program—Maternal Child Health, but also with new pro-
grams including the Village Health Worker program). NPHCDA will have funding from the National 
Health Act and will likely be a central actor with an anticipated grant for primary healthcare strength-
ening from the Bill and Melinda Gates Foundation.
State level and Local Government Areas—While state Ministries of Health are necessary for the 
adoption of policies and guidelines at the secondary level, the state Primary Health Care Development 
Agencies, the Ministry of Local Government and Chieftaincy Affairs, and the respective local govern-
ment authorities have significant operational roles to play at the primarily healthcare level.
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Community level—Collaborating with local advocacy organizations that have specific community 
engagement strategies such as PLAN and the Federation of Muslim Women Association of Nigeria will 
be important.
Training institutions—While work with the regulatory agencies at the national level and selected 
training institutions has provided evidence of workability, there is critical need to institutionalize the 
training curriculum and activities on magnesium sulfate at the institutions that train midwives and com-
munity health extension workers.
Finally, many organizations, both local and international, are now working in Nigeria to improve mater-
nal health services, including the provision of magnesium sulfate for eclampsia and pre-eclampsia, 
increasing the need for effective collaboration and coordination.
VII. Conclusion
The effort to scale up use of magnesium sulfate in the Nigeria health service delivery system to address 
the problem of pre-eclampsia and eclampsia has been impressive. Use of magnesium sulfate has gone 
from sporadic use by a handful of providers to use in more than 400 hospitals across the country in 
less than a decade. (According to the Federal Ministry of Health, in 2012 there were 1,042 secondary 
and tertiary health facilities in Nigeria.) This transition is particularly remarkable given the general chal-
lenges faced by the health infrastructure in Nigeria and the fact that magnesium sulfate involves a com-
plicated clinical protocol.
The MacArthur Foundation shepherded this scale up of the use of magnesium sulfate by bringing 
together and supporting a complementary group of players to implement a multifaceted approach.  
The approach recognized that incorporating a new clinical practice into a healthcare system takes  
careful planning, policy support, resources, and time. Through sustained funding, and by paying atten-
tion to all the components necessary for the scale up of a new technology such as magnesium sulfate, 
the MacArthur Foundation and the Federal Ministry of Health of Nigeria, working in concert with pro-
fessional societies and key research institutions, have demonstrated a successful path to saving women’s 
lives that can be adapted and replicated in other countries. The story of how Nigeria successfully 
reduced eclampsia—one of its most prevalent causes of maternal mortality—is worth telling.
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Appendix A: Nigeria Contacts List
Organization Person Contacted Position 
CEDPA Gabriel Yafeyi Program Manager
Community Health Practitioners 
Registration Board
Shiono Bennibor Registrar/CEO
Kano State MOH Dr Abubakar Labaran Yusuf Kano MoH Commissioner
Dauda Sule Kanawa Director Planning, Research & 
Statistics
Hajiya Fatima Mailafiya MCH Coordinator
Gwarzo General Hospital Binta Halilu Matron in charge of ANC 
Hadiza Labbo Matron in charge of Labor Room
KNSG Hospital, Kano Hajiya Hannatu Mohammed Formerly with the State Ministry of 
Health, Kano
Aminu Kano Teaching Hospital Dr Jamilu Tukur Consultant
MacArthur Foundation Dr. Kole Shettima Director, Africa Office
Erin Sines Acting Director, Population and 
Reproductive Health
Judith Helzner Former Director, Population and 
Reproductive Health
Harvard School of Public Health Dr. Ana Langer Professor and Coordinator of 
Dean’s Special Initiative in Women 
and Health and former CEO of 
EngenderHealth
Federal Ministry of Health Dr. Kelechi Ohiri Saving One Million Lives/FMOH
Dr Moji Odeku Former Deputy Director 
Reproductive Health, (now 
Project Director Nigerian Urban 
Reproductive Health Initiative)
Population Council Dr. Salisu Ishaku Sr. Program Manager, Nigeria
Gloria Adeoye Program Officer, Nigeria
Ian Askew Director of Reproductive Health 
Services and Research, Regional 
Office Kenya
Charlotte Warren Senior Associate, Maternal 
Newborn Health, USA
Saumya Ramarao Senior Associate, USA
Society of Gynecology and 
Obstetrics of Nigeria
Dr. Olusegun Adeoye Program Manager
Dr. Fred Achem President
UNFPA Nigeria Dr. Aliyu Yakubu Program Specialist Reproductive 
Health
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Appendix B: MacArthur Foundation Grants for Magnesium Sulfate in Nigeria 
Name of Grantee/
Organization
Purpose Duration 
of Grant
Size of 
Grant
Population Council/
Nigeria 
Scaling up the use of magnesium sulfate for the 
treatment of eclampsia in northern Nigeria, 
including a focus on hospitals, on community 
level, and on the use of technology to improve 
maternal health outcomes. Renewal grant 
included support for policy advocacy for the 
use of magnesium sulfate for the management 
of eclampsia across all levels of the Nigerian 
healthcare delivery system; developing and test-
ing a national curriculum for the pre-service 
training of nurses/midwives and community 
health extension workers on magnesium sul-
fate; and trainings to enable lower-cadre medi-
cal staff to identify and manage ‘imminent’ cases 
of eclampsia 
46 months 
(2008; 
closed) 
36 months 
(2011; 
closed) 
36 months 
(2014; in 
force)
$927,000 of 
$2.4M;
$608,000 of 
$2.2M
$650,000 of 
$2.2M
Federal Ministry of 
Health 
To pilot the administration of magnesium sul-
fate for the treatment of pre-eclampsia and 
eclampsia 10–12 states in Nigeria. 
66 months 
(2008; in 
force) 
$500,000 
EngenderHealth To develop and test an e-learning module on 
the use of magnesium sulfate for the treatment 
of eclampsia, through partnership with Oxford 
University’s Maternal and Perinatal Health Institute. 
12 months 
(2008; 
closed)
$310,000
Society of Gynecology 
and Obstetrics of 
Nigeria 
Training of service providers on current evi-
dence-based interventions for promoting safe 
motherhood, including magnesium sulfate for 
the prevention and treatment of eclampsia and 
misoprostol for the prevention of postpartum 
hemorrhage. 
36 months 
(2007; 
closed) 
A portion of 
$250,000 
Ipas Build the knowledge and skills of medical 
interns at three teaching hospitals to provide 
reproductive and maternal healthcare, including 
use of magnesium sulfate to prevent eclampsia.
36 months 
(2012; in 
force)
$500,000
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